<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04851054</url>
  </required_header>
  <id_info>
    <org_study_id>2015/6097/I</org_study_id>
    <nct_id>NCT04851054</nct_id>
  </id_info>
  <brief_title>Postoperative VEGF and Recurrence After Colon Cancer Surgery</brief_title>
  <official_title>Postoperative Serum VEGF Concentration as an Independent Prognostic Factor for Recurrence After Curative Colon Cancer Surgery. Multicentric Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital del Mar</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Germans Trias i Pujol Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital de Granollers</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Althaia Xarxa Assistencial Universitària de Manresa</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hospital Universitari Joan XXIII de Tarragona.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital del Mar</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to study the relationship between the angiogenic response to&#xD;
      surgical aggression, determined through the serum levels of vascular endothelial growth&#xD;
      factor (VEGF) on postoperative day four, and the tumor recurrence in patients with colon&#xD;
      cancer operated with a curative intention.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      DESIGN: Prospective multicentric study.&#xD;
&#xD;
      PARTICIPATION: Colorectal Surgery Units of Hospital del Mar, Barcelona; Hospital Universitari&#xD;
      Joan XXIII, Tarragona; Hospital Universitari La Fe, Valencia; Hospital Clínico San Carlos,&#xD;
      Madrid; Hospital General de Granollers, Granollers; Hospital Germans Trias i Pujol, Badalona;&#xD;
      Athalaia, Xarxa Assistencial Universitària de Manresa, Manresa&#xD;
&#xD;
      STUDY SUBJECTS: 280 consecutive patients with non-metastatic colon cancer in whom a curative&#xD;
      intent resection is performed.&#xD;
&#xD;
      DETERMINATIONS: Determination of the proangiogenic cytokine VEGF in serum on the&#xD;
      postoperative day four to assess its relationship with oncological results on long-term&#xD;
      follow-up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 1, 2017</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Actual">March 30, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>VEGF in serum on postop day 4</measure>
    <time_frame>Postoperative day 4</time_frame>
    <description>A 10cc sample of peripheral blood will be drawn on postoperative day 4</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Angiogenesis</condition>
  <condition>Colon Cancer</condition>
  <condition>Surgery</condition>
  <condition>Recurrence</condition>
  <condition>VEGF Overexpression</condition>
  <arm_group>
    <arm_group_label>Patients after surgery for colon cancer with intention to cure</arm_group_label>
    <description>Patients with colon cancer admitted to the Colorectal Surgery Unit of the centers participating in the study, who will undergo elective surgical resection with potentially curative intention</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery for colon cancer with intention to cure</intervention_name>
    <description>Surgery by open or laparoscopic approach</description>
    <arm_group_label>Patients after surgery for colon cancer with intention to cure</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum samples stored at -80ºC&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with colon cancer admitted to the Colorectal Surgery Unit of the centers&#xD;
        participating in the study, who will undergo elective surgical resection with potentially&#xD;
        curative intention.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with colon cancer admitted to the Colorectal Surgery Unit of the centers&#xD;
             participating in the study,&#xD;
&#xD;
          -  Patients who will undergo elective surgical resection with potentially curative&#xD;
             intention&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with metastatic disease&#xD;
&#xD;
          -  Patients with synchronous colon neoplasia or in the previous five years&#xD;
&#xD;
          -  Patients undergoing emergency surgery&#xD;
&#xD;
          -  Patients who do not sign the informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MIGUEL PERA, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Hospital del Mar</affiliation>
  </overall_official>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 11, 2021</study_first_submitted>
  <study_first_submitted_qc>April 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 20, 2021</study_first_posted>
  <last_update_submitted>April 14, 2021</last_update_submitted>
  <last_update_submitted_qc>April 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital del Mar</investigator_affiliation>
    <investigator_full_name>Marta Pascual</investigator_full_name>
    <investigator_title>CHIEF, COLON AND RECTAL SURGERY, DEPARTMEN OF SURGERY</investigator_title>
  </responsible_party>
  <keyword>VEGF</keyword>
  <keyword>Colon Cancer</keyword>
  <keyword>Surgery</keyword>
  <keyword>Recurrence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colonic Neoplasms</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

